Chinese biotech NetVation DL Medicine has arrived on the scene with a two-year alliance with Pfizer, plus an equity investment from the big pharma group.

Voyager Therapeutics’ chief and founder Steven Paul, M.D., is stepping down to become an “executive science advisor.”

After a deal for Immunomedics fell through last May, Seattle Genetics has scaled down spending to ink a $614 million deal for Cascadian Therapeutics.

Vical, hit with trial flop after trial flop—including a cytomegalovirus vaccine licensed from Astellas—is letting go of around half of its workforce.

Corbus will enroll 415 patients in a phase 2b trial using pulmonary exacerbations as its primary endpoint.

The asset is a recombinant protein designed by AB Biosciences to improve on existing intravenous immunoglobulin therapies.

Sanofi’s €45-a-share cash bid enabled it to leapfrog Novo Nordisk in the race to buy Ablynx and land its second big-ticket takeover of the month. 

Allergan, flush from a series of small and midsized deals over the past 18 months, is reported to be seeking a buyout of women’s health company KaNDy…